

1/6

FIG. 1

• **Study Schema:**





FIG. 2



3/6

FIG. 3

	Ficlatuzumab N=27	Combination N=33	Comparison p-value
Sex, n (%)			0.28
Female	6 (22%)	3 (9%)	
Male	21 (78%)	30 (91%)	
Age: Median (Range)	65 (37-83)	63 (46-75)	0.66
Ethnicity			1.00
Hispanic or Latino	3 (12%)	3 (9%)	
Non-Hispanic	23 (88%)	29 (91%)	
Unknown	1 (4%)	1 (3%)	
Race^a			1.00
White	24 (92%)	30 (94%)	
Black	1 (4%)	2 (6%)	
Asian	1 (4%)	0 (0%)	
Primary Site			0.58
Oral Cavity	8 (30%)	6 (18%)	
Oropharynx	11 (41%)	19 (58%)	
Larynx	3 (11%)	4 (12%)	
Other ^a	5 (19%)	4 (12%)	
HPV Positive, n (%)	10 (37%)	16 (48%)	0.44
Months since Cetuximab: Median (Range)	2.7 (0-62.6)	3.6 (0.4-47.9)	0.66
Previous Anti-PD1 mAb, n (%)	23 (85%)	31 (94%)	0.39
Platinum Resistant, n (%)	19 (70%)	24 (73%)	0.84
ECOG Performance Status			0.18
0	9 (33%)	6 (18%)	
1	18 (67%)	27 (82%)	

a. Other: EBV- nasopharynx (2), paranasal sinus (1), external auditory canal (1), unknown primary (1)

FIG. 4

	Ficlatuzumab N=26		Ficlatuzumab + Cetuximab N=32	
	Grade 1-2	Grade ≥ 3	Grade 1-2	Grade ≥ 3
Cardiovascular				
Edema				
Peripheral	4 (15%)	0	5 (16%)	1 (3%)
Facial/HH	2 (8%)	1 (4%)	1 (3%)	0
Cardiopulmonary Arrest	0	0	0	1 (3%) ^a
Constitutional				
Fatigue	2 (8%)	0	0	1 (3%)
Weight Loss	0	0	1 (3%)	0
Dermatologic				
Acneiform Rash	1 (4%)	0	14 (44%)	6 (19%)
Maculopapular Rash	0	1 (4%)	1 (3%)	0
Paronychia	0	0	2 (6%)	1 (3%)
Skin Infection	1 (4%)	0	1 (3%)	0
Gastrointestinal				
Anorexia	0	0	1 (3%)	0
Diarrhea	0	0	0	1 (3%)
Elevated AST/ALT	0	0	0	1 (3%)
Oral mucositis	0	0	3 (9%)	0
Metabolic				
Hypoalbuminemia	8 (30%)	0	10 (31%)	0
Pulmonary				
Pneumonitis	0	2 (8%) ^a	1 (3%)	0

a. Two treatment-related deaths occurred: 1 pneumonitis (ficlatuzumab arm) and 1 cardiopulmonary arrest not otherwise specified (combination arm)

FIG. 5A




FIG. 5B




FIG. 6A

	Ficlatuzumab + Cetuximab (N=32)	p-value
ORR ^a		0.02
HPV+	0/16 (0%)	
HPV-	2CR + 4PR/16 (38%)	
Median PFS ^b		0.03
HPV+	2.3 (1.9)	
HPV-	(2.9)	

a. ORR = CR + PR/n
b. Median PFS: Months (lower bound 90% 1-sided CI)

FIG. 6B

